Bepranemab for Alzheimer's Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing bepranemab, a new medication, to see if it can help people with early-stage Alzheimer's disease. The study focuses on individuals who are just starting to show symptoms or have mild symptoms. Bepranemab works by removing harmful proteins from the brain that are linked to Alzheimer's.
Will I have to stop taking my current medications?
The trial requires that you stop taking certain medications, such as atypical antipsychotics, opiates, opioids, benzodiazepines, barbiturates, hypnotics, or any medication with significant antihistamine or anticholinergic effects. If you are on these medications, you may need to stop them before participating.
Who Is on the Research Team?
UCB Cares
Principal Investigator
001 844 599 2273 (UCB)
Are You a Good Fit for This Trial?
This trial is for people aged 50-80 with mild cognitive impairment or mild Alzheimer's, as defined by specific criteria. They must have a certain level of memory function and an informant who can report on their condition. Those with other cognitive conditions, recent experimental therapy use, or certain medication histories are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Double-blind Treatment
Participants receive either bepranemab or placebo to evaluate efficacy, safety, and tolerability
Open-label Extension
Participants may opt into continuation of treatment with bepranemab long-term
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Bepranemab
Find a Clinic Near You
Who Is Running the Clinical Trial?
UCB Biopharma SRL
Lead Sponsor
Jean-Christophe Tellier
UCB Biopharma SRL
Chief Executive Officer since 2015
MD from University of Reims Champagne-Ardenne, Rheumatology specialization from University of Paris V, Executive business programs at Harvard and INSEAD
Dr. Iris Loew-Friedrich
UCB Biopharma SRL
Chief Medical Officer since 2014
MD from University of Leuven, PhD in Medical Sciences from University of Leuven